…
Guided Therapeutics, Inc., a medical technology company, researches, develops, tests, manufactures, sells, and distributes medical devices in the United States and internationally. It offers LuViva, an advanced cervical scan non-invasive cervical cancer detection device that provides less invasive and painless alternative to conventional tests for identifying, screening, and detecting cervical cancers and precancers. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is headquartered in Peachtree Corners, Georgia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Guided Therapeutics Inc is a small medical-device company that develops non-invasive optical diagnostic technology aimed at detecting cervical disease and improving screening workflows. Long-term growth drivers may include wider adoption of point-of-care screening, potential regulatory clearances or reimbursement, and partnerships to scale commercialization, which could make the company attractive to investors seeking exposure to niche diagnostic technologies.
Material risks include limited public information and liquidity, dependence on regulatory approvals and successful commercialization, and the need for additional financing to sustain operations.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -3.20M | -2.42M | -3.49M | -4.34M | -2.07M |
| Net income | -3.20M | -2.42M | -3.49M | -4.34M | -2.07M |
| Selling general administrative | 2.47M | 1.58M | 3.27M | 3.19M | 2.31M |
| Gross profit | 0.57M | 0.00M | 0.04M | -0.07M | 0.02M |
| Reconciled depreciation | 0.11M | 0.10M | 0.09M | 0.07M | 0.08M |
| Ebit | - | - | - | - | -2.36M |
| Ebitda | - | - | - | -3.69M | -0.84M |
| Operating income | -2.37M | -2.11M | -3.46M | -3.33M | -2.36M |
| Interest expense | 0.62M | 0.38M | 0.28M | 0.58M | 1.15M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.00M | 0.00M | 0.01M | 0.00M | - |
| Net interest income | -0.62M | -0.38M | -0.27M | -0.58M | -1.15M |
| Total revenue | 0.77M | 0.01M | 0.10M | 0.01M | 0.08M |
| Total operating expenses | 3.14M | 2.12M | 3.56M | 3.35M | 2.44M |
| Cost of revenue | 0.20M | 0.01M | 0.06M | 0.08M | 0.06M |
| Total other income expense net | -0.21M | 0.07M | 0.24M | -0.43M | 1.44M |
| Net income from continuing ops | -3.20M | -2.42M | -3.49M | -4.34M | -2.07M |
| Net income applicable to common shares | - | - | - | - | -2.43M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1.32M | 1.38M | 1.67M | 3.37M | 2.04M |
| Other current assets | 0.09M | 0.17M | 0.16M | 0.14M | 0.38M |
| Total liab | 7.33M | 6.27M | 5.47M | 6.25M | 7.49M |
| Total stockholder equity | -6.01M | -4.89M | -3.81M | -2.88M | -5.45M |
| Other current liab | 0.04M | 0.12M | - | - | 1.04M |
| Common stock | - | - | - | - | 3.40M |
| Capital stock | 5.09M | 6.45M | 6.46M | 6.52M | 10.27M |
| Retained earnings | -157.06M | -153.71M | -151.12M | -147.36M | -142.39M |
| Other liab | - | - | - | - | 0.03M |
| Other assets | - | - | - | - | 0.02M |
| Cash | 0.06M | 0.39M | 0.59M | 2.31M | 0.64M |
| Total current liabilities | 6.64M | 6.16M | 4.81M | 4.87M | 5.69M |
| Net debt | 2.18M | 1.62M | 1.12M | - | 1.86M |
| Short long term debt | 2.20M | 1.94M | 1.20M | 0.81M | 1.07M |
| Property plant equipment | - | - | - | - | 0.39M |
| Total current assets | 0.60M | 1.20M | 1.39M | 3.00M | 1.64M |
| Net tangible assets | - | - | - | - | -12.32M |
| Net receivables | 0.00M | 0.00M | 0.01M | 0.01M | 0.05M |
| Long term debt | 0.04M | 0.06M | 0.51M | 1.13M | 1.43M |
| Inventory | 0.45M | 0.63M | 0.63M | 0.55M | 0.57M |
| Accounts payable | 2.45M | 2.13M | 2.02M | 2.23M | 2.45M |
| Non currrent assets other | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| Non current assets total | 0.72M | 0.18M | 0.28M | 0.36M | 0.40M |
| Capital lease obligations | 0.70M | 0.15M | 0.25M | 0.33M | 0.39M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | - | 0.00M | -0.03M | -0.01M |
| Change to liabilities | - | - | - | - | 0.43M |
| Total cashflows from investing activities | - | - | - | - | -0.01M |
| Net borrowings | 0.21M | 0.11M | -0.41M | -0.54M | -0.22M |
| Total cash from financing activities | 0.74M | 0.92M | 0.02M | 3.18M | 2.07M |
| Change to operating activities | - | - | - | - | -0.36M |
| Net income | -3.20M | -2.42M | -3.49M | -4.34M | -2.07M |
| Change in cash | -0.33M | -0.20M | -1.72M | 1.67M | 0.46M |
| Begin period cash flow | 0.39M | 0.59M | 2.31M | 0.64M | 0.18M |
| End period cash flow | 0.06M | 0.39M | 0.59M | 2.31M | 0.64M |
| Total cash from operating activities | -1.07M | -1.12M | -1.75M | -1.48M | -1.59M |
| Issuance of capital stock | - | - | 0.00M | 1.39M | 2.10M |
| Depreciation | 0.11M | 0.10M | 0.09M | 0.07M | 0.08M |
| Change to inventory | 0.18M | -0.00M | -0.08M | -0.06M | 0.03M |
| Change to account receivables | -0.01M | 0.01M | -0.00M | 0.02M | -0.02M |
| Sale purchase of stock | - | - | - | 0.00M | -0.12M |
| Other cashflows from financing activities | - | - | - | - | 0.31M |
| Change to netincome | - | - | - | - | -0.01M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.03M | 0.01M |
| Change in working capital | 0.99M | 1.00M | -0.10M | 0.55M | 0.08M |
| Stock based compensation | 0.38M | 0.12M | 1.81M | 1.38M | 0.23M |
| Other non cash items | 0.28M | 0.13M | 0.16M | 0.32M | -0.13M |
| Free cash flow | -1.07M | -1.12M | -1.75M | -1.51M | -1.61M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GTHP Guided Therapeutics Inc |
-0.01 8.33% |
0.11 | - | - | 37.13 | 106.31 | 42.50 | -5.60 |
| ABT Abbott Laboratories |
1.27 1.18% |
108.52 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
1.87 1.85% |
102.86 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-2.75 0.88% |
309.64 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-0.27 0.55% |
48.51 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Guided Therapeutics, Inc., a medical technology company, researches, develops, tests, manufactures, sells, and distributes medical devices in the United States and internationally. It offers LuViva, an advanced cervical scan non-invasive cervical cancer detection device that provides less invasive and painless alternative to conventional tests for identifying, screening, and detecting cervical cancers and precancers. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is headquartered in Peachtree Corners, Georgia.
5835 Peachtree Corners East, Peachtree Corners, GA, United States, 30092
770 242 8723
3
| Name | Title | Year Born |
|---|---|---|
| Dr. Mark L. Faupel Ph.D. | CEO, President, COO, Acting CFO, Secretary & Director | 1955 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.